Sec Form 3 Filing - Jones Erika @ Black Diamond Therapeutics, Inc. - 2021-11-18

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Jones Erika 2. Issuer Name and Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [ BDTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) See Remarks (Last) (First) (Middle) C/O BLACK DIAMOND THERAPEUTICS, INC., ONE MAIN STREET, 10TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 11/18/2021 (Street) CAMBRIDGE, MA02142 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 10.86 ( 1 ) 12/04/2029 Common Stock 25,502 D Stock Option (Right to Buy) $ 19 ( 2 ) 01/28/2030 Common Stock 10,000 D Stock Option (Right to Buy) $ 24.84 ( 3 ) 03/07/2031 Common Stock 10,800 D Stock Option (Right to Buy) $ 7.73 ( 4 ) 10/17/2031 Common Stock 4,500 D Stock Option (Right to Buy) $ 7.62 ( 5 ) 11/15/2031 Common Stock 4,500 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Jones Erika C/O BLACK DIAMOND THERAPEUTICS, INC. ONE MAIN STREET, 10TH FLOOR CAMBRIDGE, MA02142 See Remarks Signatures /s/ Brent Hatzis-Schoch, Attorney-in-Fact 11/29/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )25% of the shares subject to this option vested and became exercisable on October 28, 2020, with the reminder vesting in 36 equal monthly installments thereafter. ( 2 )25% of the shares subject to this option vested and became exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter. ( 3 )25% of the shares subject to this option shall vest and become exercisable on March 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter. ( 4 )The shares subject to this option shall vest and become exercisable in two equal annual installments, with the first installment vesting on October 18, 2022. ( 5 )The shares subject to this option shall vest and become exercisable in two equal annual installments, with the first installment vesting on November 16, 2022.

Remarks: Officer Title: Vice President, Finance and Corporate Controller

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.